DGAP-News: SYGNIS AG: SYGNIS Reports Nine-Month Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: SYGNIS AG: SYGNIS Reports Nine-Month Results for the Period ended 30 September 2014 and announces new product and commercialisation strategy

DGAP-News: SYGNIS AG / Key word(s): 9-month figures/Strategic Company Decision SYGNIS AG: SYGNIS Reports Nine-Month Results for the Period ended 30 September 2014 and announces new product and commercialisation strategy 11.11.2014 / 08:01 --------------------------------------------------------------------- Press Release SYGNIS Reports Nine-Month Results for the Period ended 30 September 2014 and announces new product and commercialisation strategy - Operating result improved by 20% - Operating expenses decreased by 21% - Net loss in 9M 2014 reduced by 17% - Corporate strategy now focusing on proprietary product development and sales - First SYGNIS kit developed and currently evaluated by an industry leading partner and potential distributor Madrid, Spain and Heidelberg, Germany, November 11, 2014 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today reported results for the first nine months ended 30 September 2014. Revenues in the first nine months 2014 amounted to EUR 0.3 million (9M 2013: EUR 0.4 million). The operating result improved by 20% to -EUR 2.3 million (9M 2013: -EUR 2.8 million). Research & development expenses decreased by EUR 0.6 million to EUR 1.2 million. Total operating expenses improved to EUR 2.7 million (9M 2013 EUR 3.4 million). Next to R&D costs they include selling, general & administrative costs of EUR 1.5 million (9M 2013: EUR 1.6 million). The net loss for the period amounted to EUR 2.4 million, 17% better compared to the prior-year period. As of 30 September 2014, cash and cash equivalents decreased to EUR 0.4 million (31 December 2013: EUR 2.2 million). Total current assets reduced to EUR 0.7 million (31 December 2013: EUR 2.5 million). Cash outflow from operating activities was EUR 2.6 million (9M 2013: EUR 2.1 million); net cash inflow from financing activities amounted to EUR 1.0 million (9M 2013: EUR 1.9 million). In the light of delays in launch and sales activities of licensing partners, SYGNIS decided to focusing its corporate product and commercialization strategy on the development of an own portfolio of kits based on its proprietary PrimPol technologies. The decision was driven by the need to decrease dependency on dominant strategic partners and the intention to keep control over projected revenue streams, as well extending the value participation in its technologies and products. During the third quarter, SYGNIS made significant progress in implementing key building blocks of the new strategy and initiated the development of the first product kit. Based on its proprietary PrimPol technology SYGNIS's first kit TruePrime(TM) for whole genome DNA amplification from single cells for use in NGS applications is expected to enter the market in January 2015. This initial kit is also being evaluated by one of the industry leading partners with the aim to integrate it into the workflow of his own NGS platform. In addition, SYGNIS is developing a series of further applications for its TruePrime(TM) range of products as well as new technologies for new kits addressing a multitude of applications for the amplification of various DNA or RNA species. These kits are planned to be launched throughout 2015 and 2016. The products will be sold directly as well as through regional and international distributors focusing on gene sequencing and NGS. In addition, SYGNIS is in negotiations with international companies to market its products through OEM (Original Equipment Manufacturer) agreements. "The third quarter of 2014 was characterized by the strategic change from a technology towards a product company in the booming NGS industry. This is a major change in our corporate product and commercialization strategy. By adding an own portfolio of newly developed kits based on our proprietary PrimPol technology to our established licensing business we will significantly increase the control of the Company's sales channels and revenue streams", Pilar de la Huerta, CEO and CFO of SYGNIS commented. "I am very proud of our researchers who completed the development of the first SYGNIS product, TruePrime(TM), in just 6 months, which expresses their strong commitment and enthusiasm to bring our own product portfolio for whole genome DNA and RNA amplification to the market", she added. "Based on the proven superiority of our products and technologies and given that our products address a highly unmet need to standardize workflows in NGS applications, we are convinced that developing and selling our own products will position us in a strong strategic position. In our new role as a product company, we can actively participate from expected growth rates in NGS and therewith maximize the value of our technology portfolio in the full interest of our shareholders." Today, NGS is seen as the fastest-growing and most lucrative segment in the genomics market with estimated annual growth rates of more than 20% in the years to come. While still mostly used in research institutions, ongoing developments for higher throughput, increased accuracy, and cost efficiency as well as value creating data management will make NGS more and more attractive for commercial applications in clinical laboratories, hospitals and in pharma companies. Market experts see huge potential with estimated global market volumes beyond US$ 8.7 billion in 2020 with an increased adoption of NGS for diagnostics, drug discovery, biomarker discovery, personalized medicine, but also in agriculture and animals research. Early September 2014, SYGNIS presented a newly characterized thermo-stable member of the recently discovered family of PrimPol polymerases at Zing DNA Polymerases Conference 2014, in Cambridge, UK. This highly recognized conference is one of the key platforms for scientific players in the field of polymerases worldwide. This year's main topic was "DNA Polymerases: Biology, Diseases and Biomedical Applications", discussing the discovery of new DNA polymerases and their potential biotechnological applications mainly in the next generation sequencing (NGS) market. At the Annual General Meeting of SYGNIS held on July 17th, 2014 shareholders representing about 83 percent of the capital approved all proposals of the Management. Main decisions were related to the discharge of the members of the Supervisory and the Management Board for the past fiscal year, the election of new members of the Supervisory Board, and the creation of new authorized capital. Mr. Werner-Friedrich Knuth Schaefer has left the Supervisory Board. Mrs. Maria Jesús Sabatés was elected as new member of the Supervisory Board. Outlook Based on the revenues and grants realized during the first nine months 2014, SYGNIS reaffirms the outlook for fiscal year 2014 updated on August 14th, 2014. Revenues (including grants) for full fiscal year 2014 are expected to be in the range of EUR 0.5 million and EUR 0.7 million. The Company expects to further improve its operating results (EBIT) significantly compared to the previous year. The financial resources available as of 30 September 2014 and the expected cash inflow during the remaining fiscal year 2014 will provide SYGNIS with liquidity that extends until the end of the year. In addition the Company is currently evaluating future financing options for 2015 and onwards. Figures for the nine months ended 30 September 2014 and comparative figures in accordance with IFRS <pre> [Numbers in EUR million] 9M 2014 9M 2013 Revenues 0.3 0.4 Total Expenses 2.7 3.4 EBIT -2.3 -2.8 Net results for the period -2.4 -2.8 Operating Cash Flow -2.6 -2.1 Liquidity as of 30 September 0.4 0.1 </pre> The interim report for the first nine months, ended 30 September 2014, is available at www.sygnis.de. For further information please contact: SYGNIS AG Pilar de la Huerta CEO/CFO Tel: +34 91 192 36 50 Email: pdelahuerta@sygnis.es ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### --------------------------------------------------------------------- 11.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: SYGNIS AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 296270 11.11.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 46

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 52

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 42

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 50

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 16

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 0

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 23

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 65

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 229

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 48

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading

Top 5 Most Recently Viewed Articles

Liberty Media Corp Achieves Milestone with Stock Surge

Updated Category News Views 203

Liberty Media Corporation Reaches New 52-Week High Liberty Media Corp (FWONA), a significant player in the media and entertainment sectors, has recently achieved a landmark 52-week high in its stock price, soaring to $75.71. This impressive rise has brought attention to the company's strong market performance, reflecting a substantial gain of 31.03% over the past year....

Continue Reading
Telegram's Pavel Durov Responds to Content Moderation Criticism

Updated Category News Views 200

Pavel Durov Addresses Concerns Over Telegram's Moderation Pavel Durov, the CEO of Telegram, has recently addressed the growing concerns about the platform’s moderation practices. In a message to his large audience of over 12 million subscribers, Durov pledged that the company would take steps to respond to the criticism regarding how Telegram handles content management....

Continue Reading
FiscalNote Expands Its Reach with New Public Sector Customers

Updated Category News Views 107

FiscalNote Expands Its Reach with New Public Sector Customers FiscalNote Holdings, Inc. (NYSE: NOTE), renowned for its AI-driven enterprise SaaS technologies, has recently made headlines by securing a myriad of new agreements across the U.S. public sector. These contracts span the federal government's three branches, showcasing the Company's celebrated suite of products...

Continue Reading
Bluejay Diagnostics to Showcase Symphony IL-6 Findings at SAEM

Updated Category News Views 117

Exciting Announcement from Bluejay Diagnostics Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has recently made a remarkable announcement that will resonate within the medical community. This innovative healthcare company has had an abstract accepted for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting. This significant event is scheduled to take...

Continue Reading
Clean Maine Carbon Launches Biochar Carbon Credits Through Puro.earth

Updated Category News Views 334

Clean Maine Carbon's Groundbreaking Initiative Clean Maine Carbon (CMC) has taken a significant step forward in sustainable carbon removal by launching its first biochar CO2 Removal Certificates (CORCs). Teaming up with Flowcarbon as its carbon development partner, CMC's move marks a pivotal moment in the quest for innovative solutions to combat climate change. The Role...

Continue Reading